Background: Classification probabilities reflect to what degree a screening test represents the true disease state and include true positive (TPF) and false positive fractions (FPF). With two tests, one can compare TPF and FPF using relative probabilities which offer advantages in terms of interpretation and statistical modeling. Our objective was to highlight how individual and relative TPF and FPF can be easily estimated and compared within a regression modeling framework. This allows the modeling of tests' accuracy while adjusting for multiple covariates, and thus provides valuable information in addition to the crude TPF and FPF. We illustrate our purpose with the G8 and VES-13 screening tests aimed at identifying elderly cancer patients in need for a comprehensive geriatric assessment (CGA).
Introduction
The accuracy of medical screening tests can be quantified using various parameters such as disease-specific classification probabilities which reflect to what degree a test represents the true disease state. These include the true positive fraction (TPF or sensitivity) and the false positive fraction (FPF or one minus the specificity). In the presence of multiple screening tests, TPF and FPF can be compared using various metrics, including absolute differences, odds ratio and relative probabilities. For tests A and B, we denote the relative TPF as rTPF(A,B) ¼ TPF(A)/TPF(B) and the relative FPF as rFPF(A,B) ¼ FPF(A)/FPF(B). Relative probabilities offer valuable advantages in terms of interpretation and statistical modeling [1] . Assuming that rTPF(A,B) ¼ 0.8 and rFPF(A,B) ¼ 2, then the TPF for test A is 80% that of test B, and FPF is twice that of test B. Various factors can influence the classification probabilities of medical tests, including the environment in which they are carried out, the characteristics of the testers and the test patients, and the operating parameters for the tests [1] . As such, assessing the diagnostic accuracy of a test should involve assessing the factors that can affect TPF and FPF. Similarly, the comparison of tests should involve an evaluation of the factors that can affect their TPF or FPF differentially.
With over half of all new cancer diagnoses occurring in patients aged over 65 years [2] and the considerable heterogeneity of this population, appropriate screening tools are required to identify frail patients before initiating cancer treatment [3] . Due to an increasing demand for validated geriatric screening tools [4] [5] [6] , we developed and validated the G8 questionnaire, aimed at identifying newly diagnosed cancer patients requiring a comprehensive geriatric assessment (CGA) [7] [8] [9] . We simultaneously assessed a commonly used screening tool, the Vulnerable Elders Survey-13 (VES-13) [10, 11] . Next, our interest was to provide a thorough assessment and comparison of these screening tools. Since we were mostly interested in the extent to which the tests reflect the true disease state, i.e. true need for a CGA, we focused on classification probabilities. To our knowledge, diagnostic accuracy of screening tests has been limited to the reporting of crude TPF and FPF, and multivariate assessment of factors likely to influence these probabilities has not been conducted yet.
Our aim was to highlight how the regression modeling framework can be particularly valuable and straightforward to describe and compare the accuracy of screening tests, while adjusting for multiple covariates. We illustrate our purpose by identifying variables that affect the classification probabilities of the G8 and the VES-13 tools, and assess whether these variables influence TPF and FPF differentially.
Methods

Study design
We compared the diagnostic accuracy of the G8 and the VES-13 tools within the ONCODAGE study, a prospective multicenter cohort based on a paired design which aimed primarily at assessing the classification performances of the G8 tool [8] . Eligible patients were older than 70 years and were included before or between any two steps within the first-line therapeutic sequence for various types of cancer.
During the first visit to the cancer specialist, patients received a full clinical examination and completed the G8 and the VES-13. Independent of the visit with the cancer specialist, the patients were given a CGA that included the following items: mini nutritional assessment [12] , timed get up and go [13] , activities of daily living [14] instrumental activities of daily living [15] , mini mental state [16] and Geriatric Depression Scale (GDS-15 [17, 18] ), Cumulative Index Rating Scale (CIRS-G [19, 20] ). At the time of the CGA, the geriatric team was blinded to the results of the G8 and VES-13 tests.
To define the gold-standard or reference standard, we used the scores of each of the seven questionnaires included in the CGA. Impaired scores for each of the seven questionnaires were established according to cutoffs previously defined in the literature [7] . We considered the reference test to be normal if all scores were normal, and altered otherwise.
The G8 score ranged from zero to 17 (supplementary material S1, available at Annals of Oncology online), with lower scores indicating greater functional impairments. The cut-off value for an impaired score was set below or equal to 14 [7] . VES-13 was scored from 0 to 10 (supplementary material S2, available at Annals of Oncology online), and a score greater than 3 indicated impairment [10, 11] .
The protocol was approved by institutional review boards of participating centers and the regional ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III), and was conducted in accordance with the Declaration of Helsinki, Good Clinical Practices (Clinical Trial registration: NCT00963911). Informed consent was obtained from all participants.
Statistical methods
We defined a case as a patient eligible in the ONCODAGE study, with no major study deviations, with the G8 and VES-13 scores and at least one score available from any of the instruments constituting the CGA.
Individual performances. We reported TPF and FPF for the G8 and VES-13 [with 95% confidence intervals (95% CI)] (supplementary material S3, available at Annals of Oncology online).
We carried out an a priori selection of factors likely to influence TPF and FPF: patient age (70-74, 75-79, 80-84, older than 85), sex, performance status (PS) measured with the Eastern Cooperative Oncology Group index (ECOG 1, ECOG !2), tumor site (breast, colon, lung, prostate and UAT, and NHL), tester (nurse, CRA, or oncologist for the G8; self-completed or with assistance for VES-13) and size of the investigational site (<200 or !200 inclusions).
TPF was modeled independently for each tool using a generalized linear regression model with a log link (supplementary material S3, available at Annals of Oncology online). The models for TPF were fitted to the population of patients with an abnormal reference exam. For FPF, models were fitted to the population of patients with a normal reference exam. Variables statistically significant at the 25% level in univariate analyses were included in the multivariate model. We relied on a backward manual selection approach to select covariates in the final model. When necessary or relevant (e.g. small cell sizes, same estimated parameters), qualitative variables were grouped into categories. Significance level in the final model was set at 5% (Wald or likelihood ratio tests). Once we reached a final model, we sought and tested possible interactions.
Relative performances. We reported the rTPF and rFPF (with 95%CI).
We first relied on the McNemar's statistic for paired data to test the null hypothesis of equality of TPF for two screening tests (similarly for FPF). We fitted generalized linear regression models using a log link to estimate relative probabilities (supplementary material S4, available at Annals of Oncology online). We fitted two models, one for the relative TPF and one for the relative FPF, relying on generalized estimating equations to account for the paired design [21] . Candidate covariates were those variables retained as significant when modeling TPF of A or B. Covariates were then tested one by one for significance using a 'univariate' approach in a model that included the candidate covariate, the test variable (i.e. G8 or VES-13), and an interaction term between the covariate and the test variable (supplementary material S4, available at Annals of Oncology online). Variables with significant interaction terms were included in a multivariate model along with the test variable and the interaction term. We built the final model for the relative TPF using a backward selection approach. Significance was set at 5% in the final model (Wald or likelihood ratio tests). We modeled the relative FPF similarly.
Results
From the 1590 eligible patients for the ONCODAGE cohort, 1435 satisfied the eligibility criteria for this study. Results are presented according to the STARD guidelines for reporting of studies on diagnostic accuracy [22] (supplementary material S5, available at Annals of Oncology online). Average age was 78.2 years (65.5) with more women (70%). The reference standard was impaired for 1151 (80%) patients. Finally, 981 (68%) and 864 (60%) patients had an abnormal score on G8 and VES-13, respectively (supplementary material S6, available at Annals of Oncology online).
Individual performances. Statistical analyses of the TPF were carried out on the 1151 patients with a positive gold-standard reference test and that of FPF were carried out on the 284 patients with a negative gold-standard reference test. We reported the distribution of covariates according to the scores of the G8 and VES-13 screening tests (Appendices 7 and 8).
TPF with the G8 was TPF(G8 For the modeling of the TPF of the G8, the final multivariate model demonstrated that factors independently associated with improved TPF were: older age; poorer PS and cancer types other than prostate cancer (P < 0.05; Table 1A ). For the TPF of the VES-13, the final multivariate model demonstrated that factors independently associated with improved TPF were older age, female sex, poorer PS, and cancer types (P < 0.05; Table 1C ). For the FPF of the G8, only age and cancer types remained in the final multivariate model (P < 0.05; Table 1B ). For the FPF of the VES-13, only age remained in the final model (P < 0.05; Table 1D ). Additional discussion of the univariate models is available in supplementary material S9, available at Annals of Oncology online.
Relative performances. The G8 correctly identified 11% more of the truly impaired elderly patients than the VES-13 [rTPFðG8; VES13Þ ¼ 1:11 (95% CI: [1.07; 1.16])]. On the other hand, the G8 incorrectly identified 38% more unimpaired patients as impaired, compared with the VES-13 [rFPFðG8; VES13Þ ¼ 1:38; 95% CI: (1.11; 1.72)]. Thus, the G8 screening test was superior in the TPF but inferior in the FPF dimension. The null hypotheses for equality of TPF and equality of FPF were rejected (McNemar tests; P < 0.0001 and P ¼ 0.0035), thus equivalence in either dimension was ruled out.
For the analysis of the relative TPF, the final model highlighted that TPF improved with older age and more advanced PS, and the relative TPF of the G8 to the VES-13 was substantially lower for older ages and lower PS (Table 2A) . For the analysis of the relative FPF, the final model highlighted that FPF decreased with older age, and the relative FPF of the G8 to the VES-13 was substantially lower for older ages (Table 2B ). Additional details of the univariate models is available in supplementary material S9, available at Annals of Oncology online.
Discussion
We provided precise information on factors independently associated with the performances of the G8 and VES-13 tests. Older age, poorer PS and cancers other than prostate cancer improved the sensitivity. Regression parameters for these covariates were slightly lower for the G8, suggesting a lower effect of these covariates on the G8 compared with the VES-13. Female sex was associated with an improved sensitivity of the VES-13, but not with the G8. In terms of relative performance, the sensitivity of the G8 was better than that of the VES-13, and this disparity was substantially lower for older ages and poorer PS. On the other hand, FPF decreased for both tools with older age, and that of the G8 was also affected by the cancer localization. In terms of relative performance, FPF of the G8 was greater than that of the VES-13, and this disparity was substantially lower for older ages.
We demonstrated that the G8 is better than the VES-13 in detecting patients in need of CGA, at the expense of misclassifying normal patients. These results are coherent with a recent systematic review [23] that compared all available screening methods with CGA. The median sensitivity for G8 was 87% with a 61% median specificity. The reported median sensitivity for VES-13 was 68% and 78% median specificity. These results, along with recommendations of the SIOG, confirm that although not perfect, G8 can definitely help identify those patients in need of full geriatric assessment. If equal attention was paid to both parameters, one could not conclude on the optimal test to use in real-life conditions, or would have to rely on summary statistics integrating both dimensions, e.g. the Youden index. However, in the context of screening, we encourage the use of G8 as failing to identify patients in need of a CGA might be more problematic than over detecting them. The observed associations between age and PS with the classification probabilities of the tools were expected, as older patients with poorer PS are those patients for whom the CGA is more likely to be impaired. These results should not question the use of screening tools in the elderly cancer population. While one would expect impaired CGA in patients in the oldest age category and with poor PS, screening tools will be particularly relevant for those patients in the intermediate categories. For instance, among those patients with good PS, 75% had an impaired goldstandard, and among those patients with youngest ages (70-74), 70% had an impaired gold-standard. Age and PS alone are not sufficient to detect those patients in need for a CGA and screening tools are expected to be beneficial in these populations.
The regression modeling framework allows one to provide a thorough assessment of classification probabilities. These probabilities can be compared using different measures. Although interpretation with absolute differences is straightforward, statistical interference is limited. Conversely, odds ratios can be easily accommodated within a logistic regression model, but interpretation is complex. Relative probabilities are easily fitted using loglinear models and interpretation is straightforward. The regression modeling framework allows assessing and comparing the diagnostic accuracy of a screening test while accounting for multiple covariates. As highlighted by Pepe, the statistical techniques such as log-linear modeling are standard and should be more frequently reported, as crude estimates, if unadjusted, are only partial findings [1] . Paired designs, as in our example, are important assets as the impact of inter-patient variability is minimized, confounding is eliminated, and results, in particular for the analysis of relative performances, are expected to be more reliable than those obtained in an unpaired design.
The analysis of factors associated with classification probabilities of screening tools was not the primary objective of the ONCODAGE study, which aimed primarily at estimating the accuracy of the G8 tool. The presented analyses should be considered exploratory rather than confirmatory. In addition, given the low prevalence of patients with a normal reference test, we might have been limited in our analysis of FPF.
Positive (PPV) and negative predictive values (NPV) also provide valuable information on screening tests but their focus is about clinical prediction rather than accuracy of the tests. Moreover, because of the different denominators involved, comparison of screening tools is not straightforward as it is not possible to rely on a common regression model. For instance, factors associated with PPV of the G8 tool are investigated within the population of patients with an abnormal score at the G8 tool, while factors associated with PPV of the VES-13 tool are investigated within the population of patients with an abnormal score at the VES-13 tool. Since the analyzed populations are different, the comparison is not as straightforward as for TPF and FPF. For exploratory purposes; however, we sought to investigate factors associated with predictive values. At the univariate levels, factors associated with improved PPV included poorer PS and more advanced disease stage for the G8 tool, and older age, poorer PS and more advanced disease stage for the VES-13 tool. Conversely, with regard to NPV for the G8, associated factors included younger age, better PS, and less advanced disease stage; only advanced disease stage was associated with NPV for the VES-13. Although these exploratory analyses were limited at the multivariate stage due to convergence issues, they tend to highlight that overall predictive values tend to be affected by factors that also affect classification probabilities. Moreover, one should also keep in mind that contrary to classification performances, predictive values are functions of the prevalence of 'being at risk' (i.e. as 'requiring a CGA'). As such, comparison of PPV and NPV across studies is limited.
With regard to the definition of the gold-standard, we considered the gold-standard to be impaired if a patient had one altered score for at least one of the seven questionnaires. Alternative thresholds taking into account one [7, [24] [25] [26] or two [7, 11, [27] [28] [29] [30] abnormal questionnaires have been proposed in the literature with different sets of questionnaires that more or less cover geriatric domains [31] . So far, no objective arguments have been raised that enable us to choose the best threshold. As highlighted by the SIOG, screening tools do not replace geriatric assessment but are recommended in a busy practice in order to identify those patients in need of full geriatric assessment. If abnormal, screening should be followed by geriatric [32] assessment and guided multidisciplinary interventions. Several tools are available with different performance. We acknowledge that G8 and VES13 are not ideal screening tools. However, the assessment of these questionnaires responds to a critical need for easy and quickto-use screening tools to identify older patients requiring more detailed assessment and possible geriatric interventions.
Conclusion
The regression modeling framework allowed us to assess factors independently associated with the individual and relative performances of screening tests. This approach, conducted in the context of a paired design, allowed us to provide detailed information on these tests as opposed to crude estimates of diagnostic accuracy.
To our knowledge, this is the first study that relies on a modeling framework to estimate and compare diagnostic accuracy of screening tools in geriatric oncology. With their strengths and limitations, both G8 and VES-13 tests represent a significant step forward in geriatric screening. In the context of screening, improved TPF of the G8, and its relatively good FPF, make it a good candidate as a geriatric screening tool. In addition, G8 appears to be less affected by external variables compared with VES-13; this might be an advantage for the G8 given heterogeneity of the elderly cancer population.
